OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Arrowhead Pharmaceuticals OCF Yield % Related Terms
Arrowhead Pharmaceuticals OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (ARWR) has a OCF Yield % of -0.33 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Arrowhead Pharmaceuticals and its competitors. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #322 out of 1419 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Arrowhead Pharmaceuticals' OCF Yield % too high?
Arrowhead Pharmaceuticals' current OCF Yield % is -0.33. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #322 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' OCF Yield % compare to BMRN and MDGL?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #322 out of 1419 companies for OCF Yield %. This places Arrowhead Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current OCF Yield % is -0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.13, compared to a current price of $79.03 — trading 51.6% above its estimated fair value. The current OCF Yield % is -0.33. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current OCF Yield % is -0.33 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of $79.03 is trading 51.6% above its estimated GF Value™ of $52.13.
GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ARWR:
OCF Yield %: -0.33
GF Value™: $52.13 vs. price of $79.03 (51.6% above fair value)
No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score
Get the complete analysis for ARWR
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARWR has been successfully added to your 
